Novoic
Novoic provides AI-enabled software for detecting cognitive impairment and Alzheimer's neuropathology through speech, supporting early detection in underserved communities and offering automated clinical assessments with high data integrity and usability.
Services
Novoic provides a range of AI-enabled software solutions for the detection of subtle cognitive impairments and Alzheimer's neuropathology through speech analysis. Their audio-verbal assessment system is fully automated and has been tested on thousands of users, offering a high-usability experience even for cognitively impaired and elderly populations. Their tools support early detection of Alzheimer's disease in underserved communities across more than 50 medical centers, enabling smart devices with a browser-based approach. The integration with SDKs and hosted versions ensures seamless integration for large multi-site trials.
Products
Novoic’s flagship product, AccuRater™, is an AI-based system for the automated rating and review of clinical assessments in CNS trials. This system has demonstrated performance at or above the level of trained human raters and can be deployed for most existing clinical assessments with broad language availability. Other prominent products include their speech-based cognitive tests, which are capable of predicting amyloid PET positivity, aiding early Alzheimer's detection. Novoic provides a dashboard for managing digital screening and monitoring at scale, featuring AI-assisted triage and built-in analytics.
Technology
Novoic designs and trains large audio and language models in-house using proprietary methods and datasets. Their technology utilizes automated speech recognition, audio standardization, and built-in quality control systems to ensure high data integrity. The models developed by Novoic accurately detect mild cognitive impairments, including subthreshold impairments in preclinical Alzheimer's disease. Novoic also developed a custom clinical transcription model for creating high-quality, segmented transcripts of audio recordings, ensuring robust and accurate analysis.
Clinical Trials
Novoic has conducted clinical trials in biomarker-confirmed prodromal and preclinical Alzheimer's settings to enhance the predictive capability and robustness of their algorithms. These trials have helped make the algorithms more equitable across diverse demographic groups. The real-world datasets gathered from various communities further improve the model's applicability and robustness to demographic variance. Automated assessments and rapid analysis outputs from these trials inform patient selection in over 50 medical centers across the United States.